-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Sanofi announced the latest results of the Phase 3 IKEMA clinical tri.
The trial is evaluating the addition of the CD38-targeting antibody Sarclisa (isatuximab) to the proteasome inhibitor Kyprolis (carfilzomib, cardinal) in patients with relapsed multiple myeloma (MM) who have received 1-3 prior anti-myeloma treatmen.
Efficacy and safety of a combination regimen (Kd) of filzomib) and dexamethaso.
The median progression-free survival (mPFS) was 12 months (95% CI: 18-21; n=123) in the Kd-treated group and 37 months in the Sarclisa+Kd-treated group (H.
=58; 95%CI: 28-40; n=17
This result represents the longest mPFS observed in a clinical study investigating a proteasome inhibitor backbone therapy in second-line treatment of relapsed .
A PFS analysis based on the US FDA recommendation on censoring rules (applicable to approved US prescribing information) showed mPFS of 28 months in the Kd treatment group and 47 months in the Sarclisa+Kd treatment group (HR= 59; 95% CI: 21 - not computable [NC.
The median time to next treatment (TTNT) was 25 months (95% CI: 19-33) in the Kd treatment group and 49 months in the Sarclisa+Kd treatment group (HR = 55; 95 %CI:36-N.
TTNT measures the time interval from the date of randomization to the date of the start of the next treatment, allowing a measure of the treatment benefit peri.
The safety and tolerability of Sarclisa observed in this analysis was consistent with the safety profile of Sarclisa in other clinical trials, and no new safety signals were observ.
Sarclisa is a monoclonal antibody drug that targets a specific epitope on the CD38 receptor on multiple myeloma cel.
Sarclisa launched in 2020 and is currently approved in several countries including the US and EU countri.
In the field of MM, Sarclisa is nearly 5 years later than the CD38 antibody drug Darzalex (Zhaoke®, daratumumab, daratumumab), which is a competing product from Johnson & Johns.
Darzalex went public in 2015 and has global sales of $023 billion in 202 By comparison, Sarclisa's sales in 2021 will be just 176 million eur.
The trial is evaluating the addition of the CD38-targeting antibody Sarclisa (isatuximab) to the proteasome inhibitor Kyprolis (carfilzomib, cardinal) in patients with relapsed multiple myeloma (MM) who have received 1-3 prior anti-myeloma treatmen.
Efficacy and safety of a combination regimen (Kd) of filzomib) and dexamethaso.
The median progression-free survival (mPFS) was 12 months (95% CI: 18-21; n=123) in the Kd-treated group and 37 months in the Sarclisa+Kd-treated group (H.
=58; 95%CI: 28-40; n=17
This result represents the longest mPFS observed in a clinical study investigating a proteasome inhibitor backbone therapy in second-line treatment of relapsed .
A PFS analysis based on the US FDA recommendation on censoring rules (applicable to approved US prescribing information) showed mPFS of 28 months in the Kd treatment group and 47 months in the Sarclisa+Kd treatment group (HR= 59; 95% CI: 21 - not computable [NC.
The median time to next treatment (TTNT) was 25 months (95% CI: 19-33) in the Kd treatment group and 49 months in the Sarclisa+Kd treatment group (HR = 55; 95 %CI:36-N.
TTNT measures the time interval from the date of randomization to the date of the start of the next treatment, allowing a measure of the treatment benefit peri.
The safety and tolerability of Sarclisa observed in this analysis was consistent with the safety profile of Sarclisa in other clinical trials, and no new safety signals were observ.
Sarclisa is a monoclonal antibody drug that targets a specific epitope on the CD38 receptor on multiple myeloma cel.
Sarclisa launched in 2020 and is currently approved in several countries including the US and EU countri.
In the field of MM, Sarclisa is nearly 5 years later than the CD38 antibody drug Darzalex (Zhaoke®, daratumumab, daratumumab), which is a competing product from Johnson & Johns.
Darzalex went public in 2015 and has global sales of $023 billion in 202 By comparison, Sarclisa's sales in 2021 will be just 176 million eur.
